Natera, Inc. (NASDAQ:NTRA) CEO Sells $12,958,888.41 in Stock

Natera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman sold 78,553 shares of the business’s stock in a transaction on Wednesday, January 22nd. The shares were sold at an average price of $164.97, for a total value of $12,958,888.41. Following the completion of the sale, the chief executive officer now owns 267,629 shares of the company’s stock, valued at $44,150,756.13. This trade represents a 22.69 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Steven Leonard Chapman also recently made the following trade(s):

• On Friday, November 15th, Steven Leonard Chapman sold 4,728 shares of Natera stock. The shares were sold at an average price of $146.41, for a total value of $692,226.48.
• On Monday, October 28th, Steven Leonard Chapman sold 3,960 shares of Natera stock. The shares were sold at an average price of $118.21, for a total value of $468,111.60.

Natera Price Performance

Shares of NTRA opened at $171.93 on Thursday. Natera, Inc. has a 12-month low of $62.96 and a 12-month high of $183.00. The business has a 50-day simple moving average of $165.35 and a two-hundred day simple moving average of $135.41. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33. The stock has a market cap of $22.70 billion, a PE ratio of -97.69 and a beta of 1.65.

Natera (NASDAQ:NTRA) last issued its earnings results on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.31. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The business had revenue of $439.80 million during the quarter, compared to analysts’ expectations of $361.43 million. During the same quarter in the prior year, the firm earned ($0.95) EPS. The business’s revenue for the quarter was up 63.9% compared to the same quarter last year. Analysts anticipate that Natera, Inc. will post -1.61 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms recently issued reports on NTRA. Morgan Stanley boosted their price target on Natera from $132.00 to $176.00 and gave the company an “overweight” rating in a research note on Thursday, November 14th. StockNews.com downgraded Natera from a “hold” rating to a “sell” rating in a research report on Thursday, November 14th. Piper Sandler upped their target price on Natera from $150.00 to $200.00 and gave the company an “overweight” rating in a research report on Monday, November 18th. Craig Hallum upped their target price on Natera from $121.00 to $157.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. Finally, TD Cowen upped their target price on Natera from $155.00 to $175.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. One research analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $160.63.

Hedge Funds Weigh In On Natera

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Farallon Capital Management LLC increased its holdings in Natera by 13.6% in the 2nd quarter. Farallon Capital Management LLC now owns 4,460,557 shares of the medical research company’s stock worth $483,034,000 after purchasing an additional 532,874 shares in the last quarter. Wellington Management Group LLP increased its stake in shares of Natera by 205.4% in the third quarter. Wellington Management Group LLP now owns 2,800,263 shares of the medical research company’s stock valued at $355,493,000 after buying an additional 1,883,481 shares during the period. Massachusetts Financial Services Co. MA increased its stake in shares of Natera by 3.6% in the third quarter. Massachusetts Financial Services Co. MA now owns 2,482,818 shares of the medical research company’s stock valued at $315,194,000 after buying an additional 85,236 shares during the period. Geode Capital Management LLC increased its stake in shares of Natera by 7.4% in the third quarter. Geode Capital Management LLC now owns 2,090,480 shares of the medical research company’s stock valued at $265,747,000 after buying an additional 143,825 shares during the period. Finally, Duquesne Family Office LLC increased its stake in shares of Natera by 2.4% in the second quarter. Duquesne Family Office LLC now owns 1,974,880 shares of the medical research company’s stock valued at $213,860,000 after buying an additional 45,500 shares during the period. Institutional investors and hedge funds own 99.90% of the company’s stock.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.